Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Basal Cell 2Neoplasms 1Melanoma 1Exanthema 1Carcinoma, Squamous Cell 1

Interventions

Gels 2Fulvestrant 2Doxycycline 2Dapsone 2ruxolitinib 1dexpanthenol 1ceterizine hydrochloride 1capivasertib 1benralizumab 1Triamcinolone Acetonide 1Tetracycline 1Sirolimus 1Provitamins 1Prednisone 1Panitumumab 1Minocycline 1Loperamide 1Irinotecan 1IFL protocol 1Hydrocortisone 1Erlotinib Hydrochloride 1Clindamycin 1Cetuximab 1Anti-Bacterial Agents 1Alpelisib 1Acitretin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Exanthema × Acitretin × Clear all
NCT01299220 2013-01-16

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

University of Pittsburgh

Phase 4 Withdrawn

Exanthema, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡